{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:28:59Z","timestamp":1774009739041,"version":"3.50.1"},"reference-count":14,"publisher":"PAGEPress Publications","issue":"3","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Pityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor after several conventional and biologic therapies failed.<\/jats:p>","DOI":"10.4081\/dr.2025.10105","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T04:12:11Z","timestamp":1736395931000},"source":"Crossref","is-referenced-by-count":0,"title":["Refractory pityriasis rubra pilaris treated with abrocitinib"],"prefix":"10.4081","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-205X","authenticated-orcid":false,"given":"Filip","family":"Rob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"22844","doi-asserted-by":"crossref","unstructured":"Ross NA, Chung H-J, Li Q, et al. Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients. JAMA Dermatol 2016;152:670\u20135.","DOI":"10.1001\/jamadermatol.2016.0091"},{"key":"22845","doi-asserted-by":"crossref","unstructured":"Joshi TP, Duvic M. Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options. Am J clin Dermatol 2024;25:243-59.","DOI":"10.1007\/s40257-023-00836-x"},{"key":"22846","doi-asserted-by":"crossref","unstructured":"Ji-Xu A, Lei DK, Worswick S, et al. Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol 2022;187:1024\u20136.","DOI":"10.1111\/bjd.21792"},{"key":"22847","doi-asserted-by":"crossref","unstructured":"Chandy RJ, Chokshi A, Tan I, Feldman SR. Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review. J Cut Med Surg 2024;12034754241238735.","DOI":"10.1177\/12034754241238735"},{"key":"22848","doi-asserted-by":"crossref","unstructured":"Strunck JL, Cutler B, Rajpal B, et al. Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels. J Invest Dermatol 2022;142:235-9.","DOI":"10.1016\/j.jid.2021.06.009"},{"key":"22849","doi-asserted-by":"crossref","unstructured":"Abduljawad M, Alsharif TH, Gronfula AG, et al. The effectiveness of anti-interleukin-17A treatment for pityriasis rubra pilaris: A systematic review. Cureus 2023;15:6.","DOI":"10.7759\/cureus.41125"},{"key":"22850","doi-asserted-by":"crossref","unstructured":"Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol 2017;153:304\u20138.","DOI":"10.1001\/jamadermatol.2016.5384"},{"key":"22851","doi-asserted-by":"crossref","unstructured":"Ying Y, Yu-Hua L, Xiao-Yan W, Su-Chun H. A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab. Australas J Dermatol 2023;64:445\u20137.","DOI":"10.1111\/ajd.14076"},{"key":"22852","doi-asserted-by":"crossref","unstructured":"Saad M, Spurr A, Lipson J. Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: a case report. SAGE Open Med Case Rep 2023;11:2050313X231160927.","DOI":"10.1177\/2050313X231160927"},{"key":"22853","doi-asserted-by":"crossref","unstructured":"Song EJ, Al-Saedy MA, Bouch\u00e9 N. Refractory pityriasis rubra pilaris treated with upadacitinib. JAAD Case Rep 2023;35:112\u20134.","DOI":"10.1016\/j.jdcr.2023.03.004"},{"key":"22854","doi-asserted-by":"crossref","unstructured":"Li Y, Chen Z, He M, et al. Successful treatment of erythrodermic pityriasis rubra pilaris with upadacitinib. J Eur Acad Dermatol Venereol 2023;38:e593-5.","DOI":"10.1111\/jdv.19762"},{"key":"22855","unstructured":"Ying L, Xiaoyuan Z, Dawei H, et al. Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris. J Eur Acad Dermatol Venereol 2024; Mar 30."},{"key":"22856","doi-asserted-by":"crossref","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386:316\u201326.","DOI":"10.1056\/NEJMoa2109927"},{"key":"22857","doi-asserted-by":"crossref","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Derm Ther 2022;13:729-49.","DOI":"10.1007\/s13555-023-00892-5"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10105\/9554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10105\/9739","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10105\/9554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:30:58Z","timestamp":1774002658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.4081\/dr.2025.10105","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}